MyHealthPal Provider vs The eFACE Uso & Estadísticas

MyHealthPal provides clinicians with a comprehensive tool to monitor and manage wound healing and provide predictive wound healing. MyHealthPal guides healthcare professionals through getting alerts on postoperative wound healing status. Disclaimer: This app is intended for use with clinicians’ supervision. The application is not, and is not intended, for use in the diagnosis or treatment or prevention of any disease. Users use this at their own risk, and health care providers should exercise their own professional judgment when using this app. This app is not intended to replace or add to any current procedure for wound monitoring or care in professional health care for humans.
  • App Store de Apple
  • Gratis
  • Medicina

Clasificación de tiendas

- -

Application designed to provide rapid quantitative and graphic depiction of facial function scores in patients suffering from unilateral facial paralysis, using visual analog scales. The instrument is divided into resting (static) readings, dynamic movement readings, and synkinesis (misrouting) scores. During real-time examination of the patient, or afterwards from a video clip of facial movements, the app can be used to obtain clinician-rated scores for 16 separate facial function features. Graphs provide data regarding resting facial positions, and dynamic facial movements, and synkinesis features.
  • App Store de Apple
  • Pagado
  • Medicina

Clasificación de tiendas

- -

MyHealthPal Provider frente a The eFACE: comparación de la clasificación

Comparar la tendencia de clasificación de MyHealthPal Provider en los últimos 28 días con The eFACE

Rank

No hay datos disponibles

Comparación de las clasificaciones MyHealthPal Provider frente a The eFACE por países

Comparar la tendencia de clasificación de MyHealthPal Provider en los últimos 28 días con The eFACE

No hay datos para mostrar

Compara con cualquier sitio gracias a nuestra prueba gratuita

Empieza ya
MyHealthPal Provider VS.
The eFACE

23iciembre d, 2024